Inside the research
Vericel Corporation
VCEL Research profile · latest available data
Price overview
$39.71
▲ +0.41 (+1.0%)
| 52w hi | $48.31 |
|---|---|
| 52w lo | $29.34 |
| Vol | 359.30K |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.20
| Short | -0.38 |
|---|---|
| Medium | -0.12 |
| Long | +0.00 |
computed 2026-09-27
Key fundamentals
Vericel Corporation
Healthcare · Biotechnology
| Market cap | $2.03B |
|---|---|
| Enterprise value | $1.96B |
| Trailing P/E | 82.73x |
| Forward P/E | 46.94x |
| EV / EBITDA | 63.05x |
| P / S (ttm) | 6.64x |
| Profit margin | 7.9% |
| Return on equity | 7.2% |
| Revenue growth | +22.5% |
| Debt / equity | 25.17 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.18 | |
| Sector | +0.08 | |
| Technical | -0.27 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
Risk Metrics
| Beta vs SPX | 1.11 |
|---|---|
| Corr SPX | 0.39 |
| Annual vol | 45.6% |
| Annual ret | +2.4% |
| Sharpe | 0.05 |
| Max DD | -52.5% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-30 | Earnings Release, Exhibits | read |
| 2026-05-18 | Bylaws Amendment, Exhibits | read |
| 2026-05-07 | Earnings Release, Exhibits | read |
| 2026-05-01 | Shareholder Vote, Exhibits | read |
| 2026-02-26 | Earnings Release, Exhibits | read |
| 2026-01-13 | Earnings Release, Reg FD Disclosure… | read |
| 2025-11-06 | Earnings Release, Exhibits | read |
| 2025-07-31 | Earnings Release, Exhibits | read |
| 2025-05-08 | Earnings Release, Exhibits | read |
| 2025-05-02 | Officer / Director Change, Shareholder Vote… | read |
| 2025-04-14 | Reg FD Disclosure | read |
| 2025-02-27 | Earnings Release, Exhibits | read |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 6 |
| Top-5 share | 100.0% |
| HHI | 6,816 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $146.58M | 3.29M |
| Capital Research / Capital World | $15.68M | 352.53K |
| AQR Capital Management | $12.61M | 283.33K |
| Fidelity / FMR LLC | $2.80M | 62.96K |
| Citadel Advisors | $1.57M | 35.33K |
| T. Rowe Price Group | $3.36K | 75.44K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2011–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $197.52M | +60.9% | |
| Gross profit | $172.11M | +133.9% | |
| Operating income | $11.04M | +365.6% | |
| Net income | -$3.18M | — | |
| Cash from ops | $58.16M | +34.9% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $39.30 | $39.80 | $38.74 | $39.71 | 359.30K |
| Sep 24 | $38.86 | $39.40 | $38.39 | $39.30 | 352.00K |
| Sep 23 | $39.95 | $40.10 | $38.21 | $38.79 | 434.00K |
| Sep 22 | $40.00 | $40.42 | $39.55 | $40.22 | 547.00K |
| Sep 21 | $40.08 | $40.29 | $39.05 | $39.55 | 402.20K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →